19 June 2017, Sydney, Australia: Asia Pacific specialist CRO Novotech announced today it has expanded its business offering to include central lab services through a preferred partnership agreement with Sonic Clinical Trials, an affiliate of international healthcare company, Sonic Healthcare.
Through this unique partnership, Novotech clients will be able to select from a wide menu of assays or biomarkers, access a trial-specific kit assembly service and use a single clinical trial-dedicated laboratory with a global reach, for priority processing of clinical trial samples.
Announcing the new partnership, Novotech CEO Dr. John Moller said “Novotech has always focused on offering flexible and cost effective clinical trial solutions. Through our partnership with Sonic Clinical Trials, our clients will experience a seamless integration of laboratory services and clinical trial data management by Novotech. From the start to finish, our clients are supported by a team of dedicated project managers.
“Another key benefit to our clients is the fact that Sonic Clinical Trials is pre-audited and an approved Novotech vendor. This removes our clients’ need to undertake their own central lab vendor assurance – providing a further savings in cost and clinical trial time.”
Sonic Clinical Trials is also a registered Research Service Provider (RSP) with AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science. “Sonic Clinical Trials’ RSP status assists our eligible international clients when accessing the Australian R&D Tax Incentive Scheme**. Research from a recent Frost and Sullivan white paper revealed that eligible companies can conduct early stage clinical trials 60% more cheaply in Australia than the USA,” explained Dr. Moller, “Novotech’s size and Asia Pacific focus allows our clients to enjoy a direct, hands-on approach to accessing some of the largest patient pools in the world but we balance this with providing global gold-standard central laboratory services and data management platforms.”
Contact us to hear more about the difference Novotech’s medical and central lab services could make to your clinical trial, or how we can help you access the Australian R&D Tax Incentive Scheme for your upcoming clinical trial research.
____________________
**About the Australian R&D Tax Incentive Scheme
Through the Australian R&D Tax Incentive Scheme, eligible companies may claim a 43.5% R&D tax refund on eligible R&D expenditure.
For more information about this scheme is available in the joint Novotech and Frost & Sullivan white paper, ‘Australia: The preferred destination for early phase clinical trials’.
About Novotech - www.novotech-cro.com
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech’s strong Asia Pacific presence included running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.
For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us
Media: Digital Mantra Group Susan Fitzpatrick-Napier
Ph: AU +61 2 8218 2144 / USA: +1 650 798 5238
Email: susan@dmgpr.com
Corporate enquiries
Marketing & Communications Manager Justine Lamond
Ph: +61 2 8569 1458
Email: communications@novotech-cro.com
About Sonic Clinical Trials - http://www.sonicclinicaltrials.com.au/
Sonic Clinical Trials is a wholly owned subsidiary of Australian-owned Sonic Healthcare, one of the world's largest specialist medical diagnostics companies, employing more than 33,000 people in Australia, New Zealand, the United Kingdom, Germany, Switzerland, Belgium, Ireland and the USA. Sonic Healthcare has over 20 years’ experience processing clinical trial samples from 5,000 trial sites and over 900 studies globally.
Sonic Clinical Trials provides a dedicated, superior central laboratory service, exclusively in support of Phase I-IV clinical trials, safety testing and patient monitoring services to the Pharmaceutical, Biotechnology and Research organisations in the Asia Pacific region. Sonic's sister clinical trial laboratory, TDL Trials based in London, provides extended services and capabilities throughout the United Kingdom and continental Europe. Together, we aim to meet every client's unique requirements, by offering flexible service options, high-quality results through technical excellence and local project management, whilst ensuring all regulatory requirements are met.
In addition to the depth of experience of the Australian central laboratory team, Sonic Clinical Trials can directly access the vast infrastructure and resources of Sonic Healthcare's extended group of diagnostic practices, to provide an even broader range of services and medical expertise. The group's management team has a unique depth of central laboratory experience, providing direct flow-on benefits to its clients.
Sonic Clinical Trials is a registered Research Service Provider (RSP) with AusIndustry which allows us to work with and assist our international clients register for the Australian R&D Tax Incentive Scheme. Eligible companies may claim an R&D tax offset (up to 45%) for eligible expenditure on registered R&D activities. Working with Sonic Clinical Trials as a registered RSP helps companies, particularly small to mid-size companies gain access to expert R&D resources in particular fields.
Biomarker testing
Wide range of biomarker testing* now available in the SCT laboratory including: • Apolipoprotein E • Alpha 2 macroglobulin• Complement factor D • Complement factor Bb • Alternate Complement pathway (AP-Wieslab) • CK18 M30•CXCL-8/IL-8•CXCL-9/MIG•CXCL-10/IP-10• Glucagon • Glucagon like peptide-1(Total/Total)• Hyaluronic Acid• HER2 ECD• IFN beta• IFN gamma• IL-1β• IL-6• IL-12p70• IL-18• Inhibin B • Osteopontin• Proinsulin • Pancreatic polypeptide PPP • Pancreatic peptide PYY • Sonic Hedgehog Ligand •Tumor Necrosis Factor alpha• Transforming Growth Factor 1-Beta • Vascular Endothelial Growth Factor VEGF • Chitinase 3-like1(YKL-40) • Urine NGAL • Urine Cystatin C • Urine TIM-1/KIM-1 • Urinary GSTpi • alphaGST